Brief presentation of the project idea:
Total value of the project: 724 029.14 Eur (excluding VAT). For the implementation of the project, UAB Biocentras and its partner UAB Biotechnologinė Platforma allocate at least EUR 379,738.09 of own funds. Up to EUR 344,291.05 (excluding VAT) of European Union funds is allocated for the implementation of the project.
Brief presentation of the project idea: During the implementation of the project it is planned to develop two products that currently have no analogues in the world markets: a prototype of a telomerase inhibitor and malignant cell growth inhibitor (ImunoM-T) and a prototype of an adjuvant that promotes immunization of the body with antigens and / or vaccines (ImmunoM-A), and also one product that is new to the market is a medicine designed to stimulate the immune system and stimulate the body’s anti-infective function (ImunoM-S). Brief introduction of these products:
Prototype of ImmunoM-T – a drug that inhibits the enzyme telomerase and inhibits the growth of malignant cells. The active substance of the drug – fractions of different molecular weights of the S. cerevisiae polysaccharide complex prepared according to patent WO2015159134 A1.
ImmunoM-A is a prototype of an adjuvant that promotes immunization of the body with antigens and / or vaccines (ImmunoM-A). The active substance is a complex of S. cerevisiae polysaccharide molecules of different sizes.
ImmunoM-S – a prototype of a drug that modulates the immune system and promotes anti-infective functions. The active substance of the preparation is fractions of different molecular weights of the S. cerevisiae polysaccharide complex made according to global patent WO2015159134 A1.
Institution providing financial support:
The project is financed in accordance with the European Union Regional Development Fund Investment Operational Program Priority 1 “Promotion of Research, Experimental Development and Innovation” of the European Union Regional Development Fund for 2014-2020. J05-LVPA-K “Intelligence. Joint business and research projects ”.